Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300339 · ClinicalTrials.gov registry record · Phase 2
Mixed Antagonist of Serotonin for Claudication Optimal Therapy
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 599
- Enrollment target
NCT00300339: Completed Phase 2 study, sponsored by Sanofi.
NCT00300339 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 599 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (350% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00300339, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 599 participants
- Enrollment target
Study Summary
To investigate in patients suffering from intermittent claudication due to Fontaine stage II PAD whether a 24-week treatment by SL650472 OD on top of clopidogrel may result in an improvement of walking capacity, by comparing three doses of SL650472 to placebo, and to calibrate such effect versus cilostazol
Interventions
- DRUG SL650472, Clopidogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 599 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
What the finished NCT00300339 record still lists
NCT00300339 is an interventional study that assigns participants to a tested intervention. The registered 599 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (350% higher).
The record links to 0 conditions, and to 1 intervention - of which SL650472, Clopidogrel is the first listed.
NCT00300339 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00300339 about?
NCT00300339 is a clinical study titled "Mixed Antagonist of Serotonin for Claudication Optimal Therapy". To investigate in patients suffering from intermittent claudication due to Fontaine stage II PAD whether a 24-week treatment by SL650472 OD on top of clopidogrel may result in an improvement of walking capacity, by comparing three doses of SL650472 to placebo, and to calibrate such effect versus cil...
What is the current status of trial NCT00300339?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 599 participants. The study started on 2006-02. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00300339?
The interventions under investigation include: SL650472, Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT00300339?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00300339's enrollment target sits among peer trials
599 56th of 2000 higher than 1,945 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06875973 · 599 participants · Phase 3
Pelacarsen Roll-over Extension Program
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia